Entera Bio Ltd. (NASDAQ:ENTX) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares and pre-funded warrants Closed: US$275M raised · US$2.04 a share · Leerink Partners +5 Dealers: Leerink Partners (lead), Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital, Canaccord Genuity Buyers: BVF Partners L.P. (led the private placement; granted the right to designate two directors); Longitude Capital; Vivo Capital; TCGX; Spruce Street Capital; Venrock Healthcare Capital Partners; RA Capital Management; Perceptive Advisors; Driehaus Capital Management; Logos Capital; Catalio Capital Management Use of proceeds: Fund EB613 Phase 3 program through NDA submission, advance EB612 into the clinic with OPKO, and extend cash runway into 2030 | Aug 7, 2026 |
| Strategic investment of ordinary shares Closed: US$2.17 a share Buyers: OPKO (3,685,226 ordinary shares at $2.17 per share) Use of proceeds: To fund Entera's 40% share of costs of the oral GLP-1/glucagon program through Phase 1 | Mar 17, 2025 |